Table 3.

Summary of each NSIAT included in the survey from a total of 291 participants to the survey.

	PRP	ACS	APS	Cell Therapy	Polyacrylamide hydrogel
Number of responding practitioners using product for musculoskeletal injuries	224/291; 76.9%	200/291; 68.7%	137/291; 47.1%	142/291; 48.8%	104/291; 35.7%
Number of responding practitioners using product IA	196/291; 67.4%	200/291; 68.7%	137/291; 47.1%	137/291; 47.1%	104/291; 35.7%
Top 2 reasons for practitioner use of the product	1- Ligament/ Tendon pathology (150/224; 66.9%) 2- Acute articular Pathology (25/224; 11.2%)	1-Acute articular Pathology (71/200; 35.5%) 2- Chronic articular pathology (70/200; 35%)	1- Acute articular pathology (54/137; 39.4%) 2- Chronic articular pathology (51/137; 37.2%)	1- Ligament/Tendon Pathology (71/142; 50%) 2- Acute articular pathology (25/142; 17.6%)	1- Chronic Articular Pathology (75/104; 74.3%) 2-Severe OA unresponsive to other treatments (17/104; 16.3%)
Most frequent products used in combination for IA injection	None (161/224; 71.9%)	None (147/200; 73.5%)	None (119/137; 86.9%)	None (79/142; 55.6%)	Not asked